💊 Will Acceleron Walk Away With Merck?

Huntsman surges; Facebook whistleblower to testify.


Hey Global Investor! Here’s what you need to know before the US markets open.

Market Snapshot 📈

S&P 500 (Tuesday’s Close) 4,352.63 -90.48 (2.04%)

NASDAQ (Tuesday’s Close) 14,546.68 -423.29 (2.83%)

FTSE 100 (4:30 PM IST) 7,088.53 +60.43 (0.86%)

NIFTY 50 (Today’s Close) 17,711.30 -37.30 (0.21%)

USDINR (Today’s Close) 74.16 (1 Year -1.36%)


 

🔥 Top Movers

UNFI +23.73%
LYEL +9.97%
THO +7.93%

AGMH -15.65%
INMD -12.76%
SPT -11.67%


💊 Acceleron: Blindsiding Bristol?

New Jersey-based drug-maker Merck & Co. (MRK) is in “advanced talks” to acquire biopharma company Acceleron Pharma Inc. (XLRN). Merck will pip Bristol Myers Squibb (BMY), which already holds an 11.5% stake in Acceleron if all goes well. (Tweet This)

The Inheritance

Merck is one of the oldest pharma MNCs globally, developing medicines and vaccines for over 130 years. Its drugs are used to treat many ailments, including cancer, diabetes, and HIV/AIDS. It pioneered a drug to prevent infections from the dreaded Ebola virus.

After CEO Ken Frazier retired earlier this year and became the executive chairman, CFO Rob Davis took over as CEO. Frazier had presided over Merck’s cancer drug Keytruda – which became its top-selling product and one of the best-selling drugs worldwide.

In 2020, Keytruda alone clocked annual sales of $14B and is expected to become the top-selling drug worldwide by 2023. The change of guard from Frazier to Davis happened in July, just as the world was looking to come out of the pandemic’s grip.

The object of Merck’s attention is Cambridge, Massachusetts-based Acceleron Pharma. Founded in 2003 as Phoenix Pharma, it changed its name a year later. By 2006, Acceleron had begun clinical trials for Sotatercept, a drug for treating late-stage pulmonary arterial hypertension (PAH). Acceleron currently has four drugs in clinical trials and one in pre-clinical development.

In 2008, Acceleron partnered with Celgene to jointly develop and market Sotatercept, with Celgene initially committing $55M to the arrangement, including $5M in stock.

Celgene also agreed to buy an additional $7M in stock if Acceleron were to go public (which it did in 2013). The deal also included $510M in milestone payments to be made to Acceleron.

In March 2019, Bristol-Myers Squibb acquired Celgene for $74B, and as a result, inherited the 11.5% stake that Celgene held in Acceleron.

Pretty Pipeline

Bristol and Acceleron are currently collaborating on the blood cancer drug Reblozyl in addition to Sotatercept. As such, when it was revealed last Friday that Acceleron was looking to get acquired for ~$11B or $180 per share, Bristol was expected to be the acquirer.

Turns out Merck, with Davis at the helm, managed to pull a fast one on Bristol. If the deal is signed this week, it will be one where the negotiations were conducted right under the nose of Bristol without triggering any suspicion.

Based on the terms signed by Celgene back in the day, despite the 11.5% stake it holds, Bristol does not have the power to stop any potential acquisition of Acceleron.

In the meantime, Phase II clinical trials of Sotatercept are continuing, and the results are promising. Patients are showing improvement across a broad range of outcomes, including peak oxygen uptake as well as the six-minute walk test.

These results, coupled with the upcoming Phase III testing, have triggered the expectation that Sotatercept might be a winner with peak sales of as much as $3B.

The optimistic view of Sotatercept and talk of the deal with Merck have pushed Acceleron’s stock up 20% in the past week. On the other hand, Merck’s shareholders have adopted a wait and watch approach in case Bristol manages to throw a spanner in the works.

If Merck eventually gets its prize, it will add further heft to its existing molecule pipeline. Whether Acceleron’s molecules will match Keytruda’s success is thought for another day. That, however, is not stopping Acceleron’s shareholders from salivating today!

Market Reaction
XLRN ended at $182.78, up 2.19%. Shares are up 47% this year.

Company Snapshot 📈

XLRN $182.78 +3.91 (2.19%)

Analyst Ratings (14 Analysts) BUY 79%  HOLD 21%  SELL 0%


Newsworthy 📰

Big Bucks: Activist Hedge Fund Starboard has stake worth over $500M in Huntsman Corp (HUN +6.31%)

Tough Times: Sonos CEO says this is the most challenging time for tech companies he’s ever seen (SONO -3.18%)

Case: Facebook whistleblower to testify at US Senate hearing next week (FB -3.66%)


Later Today 🕒

  • Cintas Corporation Earnings (CTAS)
  • Jabil Inc. Earnings (JBL)
  • Herman Miller Inc. Earnings (MLHR)
  • Worthington Industries Inc. Earnings (WOR)
  • 9:15 PM IST: Fed Chair Jerome Powell speaks at ECB forum

Today’s Market Terminology: Mutual Funds

A mutual fund is an open-end professionally managed investment fund that pools money from many investors to purchase securities


Disclaimer: The content of this article has been created and published by Winvesta India Technologies Pvt. Ltd., in order to ease the reader’s understanding of the subject matter. The information and/or content (collectively “Information”) provided herein is general information sourced through various news reports and does not constitute a research report or a research analysis. The Information is not intended to offer advice, target or solicit any particular customer or group of customers to buy or sell securities. 

Winvesta does not render any research or advisory services and provides a more detailed description of its services on its website and mobile application along with the terms and conditions published therein from time to time. While reasonable care has been exercised to ensure that the Information is adequate and reliable, no representation is made by Winvesta as to its accuracy or completeness and Winvesta, its affiliates, subsidiaries and employees accept no liability of whatsoever nature for any direct or consequential loss, including without limitation any loss of profits, arising from reliance on this Information. Neither Winvesta nor any of its affiliates are acting as an investment adviser, research analyst or in any other fiduciary capacity. Accordingly, reader’s are expected to undertake their own due diligence in consultation with their own advisors and are advised not to solely rely on the Information. Any such reliance shall be at the reader’s own risk. 

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing.


Start Building Your Global Portfolio Today

Download Winvesta App now to Get Started